Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays"
- PMID: 31451575
- PMCID: PMC6711895
- DOI: 10.1128/JCM.00984-19
Reply to Murray et al., "Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays"
Comment on
-
GeneXpert MTB/RIF Is Superior to BBD Max MDR-TB for Diagnosis of Tuberculosis (TB) in a Country with Low Incidence of Multidrug-Resistant TB (MDR-TB).J Clin Microbiol. 2019 May 24;57(6):e00537-19. doi: 10.1128/JCM.00537-19. Print 2019 Jun. J Clin Microbiol. 2019. PMID: 30971464 Free PMC article. No abstract available.
-
Comparative Performance of BD MAX MDR-TB and Cepheid Xpert MTB/RIF Assays.J Clin Microbiol. 2019 Aug 26;57(9):e00779-19. doi: 10.1128/JCM.00779-19. Print 2019 Sep. J Clin Microbiol. 2019. PMID: 31451572 Free PMC article. No abstract available.
References
-
- Mokaddas E, Ahmad S, Eldeen HS, Al-Mutairi N. 2015. Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 culture system for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence. J Clin Microbiol 53:1351–1354. doi:10.1128/JCM.03412-14. - DOI - PMC - PubMed
-
- Mokaddas E, Ahmad S, Samir I. 2008. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996–2005. Int J Tuberc Lung Dis 12:319–325. - PubMed
-
- Al-Mutairi NM, Ahmad S, Mokaddas E, Eldeen HS, Joseph S. 2019. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis. BMC Infect Dis 19:3. doi:10.1186/s12879-018-3638-z. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical